Details of Drug

Details of Drug

 Drug General Information (ID: D0886)
  Drug Name
Lactic acid
  Drug Type Small molecule
  Drug Synonymous
lactic acid; 2-hydroxypropanoic acid; DL-Lactic acid; 50-21-5; 2-hydroxypropionic acid; Milk acid; lactate; Polylactic acid; Tonsillosan; Racemic lactic acid; Ordinary lactic acid; Ethylidenelactic acid; Propanoic acid, 2-hydroxy-; Lactovagan; Acidum lacticum; Kyselina mlecna; DL-Milchsaeure; alpha-Hydroxypropionic acid; 26100-51-6; 1-Hydroxyethanecarboxylic acid; Lactic acid, dl-; Aethylidenmilchsaeure; Lacticum acidum; (RS)-2-Hydroxypropionsaeure; FEMA No. 2611; 598-82-3; Kyselina 2-hydroxypropanova; Propionic acid, 2-hydroxy-; CCRIS 2951; HSDB 800; (+-)-2-Hydroxypropanoic acid; Lactic acid, tech grade; Propanoic acid, hydroxy-; SY-83; alpha-Hydroxypropanoic acid; DL- lactic acid; NSC 367919; AI3-03130; Purac FCC 80; Purac FCC 88; MFCD00004520; (R)-2-Hydroxy-propionic acid;H-D-Lac-OH; CHEBI:78320; Poly(L-lactide); Lactic acid USP; NSC-367919; NCGC00090972-01; 2-hydroxy-propionic acid; Lactic acid (natural); E 270; DSSTox_CID_3192; (+/-)-Lactic acid; C01432; DSSTox_RID_76915; DSSTox_GSID_23192; Milchsaure [German]; Milchsaure; FEMA Number 2611; Kyselina mlecna [Czech]; Cheongin samrakhan; UNII-3B8D35Y7S4; CAS-50-21-5; Cheongin Haewoohwan; Cheongin Haejanghwan; Kyselina 2-hydroxypropanova [Czech]; EINECS 200-018-0; EINECS 209-954-4; Lactic acid [USP:JAN]; EPA Pesticide Chemical Code 128929; BRN 5238667; lactasol; 1-Hydroxyethane 1-carboxylic acid; Biolac; Lurex; 2-Hydroxy-2-methylacetic acid; Lactide Polymer; MFCD00064266; Chem-Cast; L- Lactic acid; DL-Polylactic acid; Lactate (TN); Lactic acid,buffered; 3B8D35Y7S4; 2-Hydropropanoic acid; 2-Hydroxypropionicacid; 4b5w; (+,-)-Lactic acid; Propanoic acid, (+-); HIPURE 88; (.+/-.)-Lactic acid; EC 200-018-0; Lactic acid (7CI,8CI); Lactic acid (JP17/USP); Lactic acid, 85%, FCC; NCIOpen2_000884; .alpha.-Hydroxypropanoic acid; .alpha.-Hydroxypropionic acid; Lactic acid, unspecified form; (RS)-2-hydroxypropanoic acid; Lactic Acid (Fragrance Grade); INS NO.270; DL-Lactic Acid (90per cent); L-(+)-Lactic acid, 98%; CHEMBL1200559; DTXSID7023192; Lactic acid, natural, >=85%; (+/-)-2-hydroxypropanoic acid; BDBM23233; L-lactic acid or dl-lactic acid; DL-Lactic acid, ~90% (T); INS-270; DL-Lactic acid, AR, >=88%; DL-Lactic acid, LR, >=88%; Propanoic acid, 2-hydroxy- (9CI); Tox21_111049; Tox21_202455; Tox21_303616; BBL027466; NSC367919; STL282744; AKOS000118855; AKOS017278364; Tox21_111049_1; AM87208; DB04398; MCULE-5387110670; SB44647; SB44652; DL-Lactic acid, 85 % (w/w), syrup; Propanoic acid,2-hydroxy-,(.+/-.)-; NCGC00090972-02; NCGC00090972-03; NCGC00257515-01; NCGC00260004-01; 26811-96-1; I487; Lactic acid, 1.0N Standardized Solution; DB-071134; E-270; FT-0624390; FT-0625477; FT-0627927; FT-0696525; FT-0774042; L0226; Lactic acid solution, ACS reagent, >=85%; Lactic acid solution, USP, 88.0-92.0%; Lactic acid solution, p.a., 84.5-85.5%; Lactic acid, meets USP testing specifications; D00111; PROPANOIC ACID, 2-HYDROXY-, (.+-.)-; A877374; DL-Lactic acid, SAJ first grade, 85.0-92.0%; Q161249; DL-Lactic acid, JIS special grade, 85.0-92.0%; Lactic acid solution, Vetec(TM) reagent grade, 85%; F2191-0200; BC10F553-5D5D-4388-BB74-378ED4E24908; Lactic acid, United States Pharmacopeia (USP) Reference Standard; Lactic acid, Pharmaceutical Secondary Standard; Certified Reference Material; DL-Lactic acid 90%, synthetic, meets the analytical specifications of Ph. Eur.
    Click to Show/Hide
  Therapeutic Class Topical Agents
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C3H6O3
  InChI InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)
  InChIKey JVTAAEKCZFNVCJ-UHFFFAOYSA-N
  Canonical SMILES CC(C(=O)O)O
  External Link
Pubchem ID 612
VARIDT ID DR01241

Drug-Drug Interaction Network
  Sunburst Graph
AM005  Affected excretion pathways
BM029  Altered urine pH
  Relation Graph
 Full list of drugs interacting with Lactic acid
      Affected excretion pathways
   Altered urine pH Drug Num:  30
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0017
 
Acetylsalicylic acid
 
C9H8O4
 
2244 
Moderate    Inter Info   
[1], [2], [3]
D0074
 
Amphetamine
 
C9H13N
 
3007 
Moderate    Inter Info   
[4], [5], [6]
D0165
 
Benzphetamine
 
C17H21N
 
5311017 
Moderate    Inter Info   
[4], [5], [6]
D0441
 
Demeclocycline
 
C21H21ClN2O8
 
54680690 
Moderate    Inter Info   
[7], [8], [9]
D0465
 
Dextroamphetamine
 
C9H13N
 
5826 
Moderate    Inter Info   
[4], [5], [6]
D0530
 
Doxycycline
 
C22H24N2O8
 
54671203 
Moderate    Inter Info   
[7], [8], [9]
D0579
 
Ephedrine
 
C10H15NO
 
9294 
Moderate    Inter Info   
[10], [11], [12]
D0580
 
Ephedrine (nasal)
 
C10H15NO
 
9294 
Moderate    Inter Info   
[10], [11], [12]
D0331
 
Choline salicylate
 
C12H19NO4
 
54686350 
Moderate    Inter Info   
[1], [2], [3]
D0940
 
Lithium carbonate
 
CLi2O3
 
11125 
Moderate    Inter Info   
[13], [14], [15]
D1020
 
Methenamine
 
C6H12N4
 
4101 
Moderate    Inter Info   
[16], [17], [18]
D0937
 
Lisdexamfetamine
 
C15H25N3O
 
11597698 
Moderate    Inter Info   
[4], [5], [6]
D0983
 
Mecamylamine
 
C11H21N
 
4032 
Moderate    Inter Info   
[19]
D1012
 
Metamfetamine
 
C10H15N
 
10836 
Moderate    Inter Info   
[4], [5], [6]
D1070
 
Minocycline
 
C23H27N3O7
 
54675783 
Moderate    Inter Info   
[7], [8], [9]
D1209
 
Oxytetracycline
 
C22H24N2O9
 
54675779 
Moderate    Inter Info   
[7], [8], [9]
D1363
 
Pseudoephedrine
 
C10H15NO
 
7028 
Moderate    Inter Info   
[10], [11], [12]
D1371
 
Quinidine
 
C20H24N2O2
 
441074 
Moderate    Inter Info   
[20], [21], [22]
D1439
 
Salicylic acid (sodium)
 
C7H6O3
 
338 
Moderate    Inter Info   
[1], [2], [3]
D1442
 
Salsalate
 
C14H10O5
 
5161 
Moderate    Inter Info   
[1], [2], [3]
D1564
 
Tetracycline
 
C22H24N2O8
 
54675776 
Moderate    Inter Info   
[7], [8], [9]
D0013
 
Acetohexamide
 
C15H20N2O4S
 
1989 
Minor    Inter Info   
[23], [24], [25]
D0325
 
Chlorpropamide
 
C10H13ClN2O3S
 
2727 
Minor    Inter Info   
[23], [24], [25]
D0664
 
Flecainide
 
C17H20F6N2O3
 
3356 
Minor    Inter Info   
[26]
D0728
 
Glipizide
 
C21H27N5O4S
 
3478 
Minor    Inter Info   
[23], [24], [25]
D0730
 
Glyburide
 
C23H28ClN3O5S
 
3488 
Minor    Inter Info   
[23], [24], [25]
D0998
 
Memantine
 
C12H21N
 
4054 
Minor    Inter Info   
[27]
D1025
 
Methotrexate
 
C20H22N8O5
 
126941 
Minor    Inter Info   
[28], [29], [30]
D1601
 
Tolazamide
 
C14H21N3O3S
 
5503 
Minor    Inter Info   
[23], [24], [25]
D1603
 
Tolbutamide
 
C12H18N2O3S
 
5505 
Minor    Inter Info   
[23], [24], [25]
References
1 Berg KJ "Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency." Eur J Clin Pharmacol 11 (1977): 111-6. [PMID: 837963]
2 Brouwers JRBJ, Desmet PAGM "Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs." Clin Pharmacokinet 27 (1994): 462-85. [PMID: 7882636]
3 Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT "Diuresis or urinary alkalinisation for salicylate poisoning?" Br Med J (Clin Res Ed) 285 (1982): 1383-6. [PMID: 6291695]
4 Anggard E, Jonsson LE, Hogmark AL, Gunne LM "Amphetamine metabolism in amphetamine psychosis." Clin Pharmacol Ther 14 (1973): 870-80. [PMID: 4729903]
5 Davis JM, Kopin IJ, Lemberger L, Axelrod J "Effects of urinary pH on amphetamine metabolism." Ann N Y Acad Sci 179 (1971): 493-501. [PMID: 5285389]
6 Wilkinson GR, Beckett AH "Absorption, metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output." J Pharmacol Exp Ther 162 (1968): 139-47. [PMID: 5656593]
7 Elliott GR "Sodium bicarbonate and oral tetracycline." Clin Pharmacol Ther 13 (1972): 459. [PMID: 5026384]
8 Jaffe JM, Colaizzi JI, Poust RI, McDonald RH Jr "Effect of altered urinary pH on tetracycline and doxycycline excretion in humans." J Pharmacokinet Biopharm 1 (1973): 267-82.
9 Jaffe JM, Poust RI, Feld SL, Colaizzi JL "Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans." J Pharm Sci 63 (1974): 1256-60. [PMID: 4852448]
10 Brater DC, Kaojarern S, Benet LZ, et al "Renal excretion of pseudoephedrine." Clin Pharmacol Ther 28 (1980): 690-4. [PMID: 7438686]
11 Kuntzman RG, Tsai I, Brand L, Mark LC "The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma." Clin Pharmacol Ther 12 (1971): 62-7. [PMID: 5541135]
12 Wilkinson GR, Beckett AH "Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output." J Pharmacol Exp Ther 162 (1968): 139-47. [PMID: 5656593]
13 Parfrey PS, Ikeman R, Anglin D, Cole C. Severe lithium intoxication treated by forced diuresis. Can Med Assoc J. 1983 Nov 1;129(9):979-80
14 Arthur RK "Lithium levels and "Soda Bic"." Med J Aust 2 (1975): 918
15 Thomsen K, Schou M "Renal lithium excretion in man." Am J Psychol 215 (1968): 823-7
16 Kevorkian C, Merritt J, Ilstrup D "Methenamine mandelate with acidification: an effective urinary antiseptic in patients with neurogenic bladder." Mayo Clin Proc 59 (1984): 523. [PMID: 6379319]
17 Musher D, Griffith D "Generation of formaldehyde from methenamine: effect of pH and concentration, and antibacterial effect." Antimicrob Agents Chemother 6 (1974): 708-11. [PMID: 4451344]
18 Product Information. Hiprex (methenamine). Hoechst Marion-Roussel Inc, Kansas City, MO.
19 Allanby KD, Trounce JR "Excretion of mecamylamine after intravenous and oral administration." Br Med J 2 (1957): 1219-21. [PMID: 13472094]
20 Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90. [PMID: 6882885]
21 Romankiewicz JA, Reidenberg M, Drayer D, Franklin JE "The noninterference of aluminum hydroxide gel with quinidine sulfate absorption: An approach to control quinidine-induced diarrhea." Am Heart J 96 (1978): 518-20
22 Mauro VF, Mauro LS, Fraker TD Jr, Temesy-Armos PN, Somani P "Effect of aluminum hydroxide gel on quinidine gluconate absorption." DICP 24 (1990): 252-4
23 Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6. [PMID: 1646724]
24 Neuvonen PJ, Karkkainen S "Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics." Clin Pharmacol Ther 33 (1983): 386-93. [PMID: 6297841]
25 Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72. [PMID: 6781341]
26 Hertrampf R, Gundert-Remy U, Beckmann J, et al "Elimination of flecainide as a function of urinary flow rate and pH." Eur J Clin Pharmacol 41 (1991): 61-3. [PMID: 1782979]
27 Product Information. Namenda (memantine). Forest Pharmaceuticals, St. Louis, MO.
28 Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G "High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity." Cancer Treat Rep 61 (1977): 779-83. [PMID: 302143]
29 Sand TE, Jacobsen S "Effect of urine pH and flow on renal clearance of methotrexate." Eur J Clin Pharmacol 19 (1981): 453-6. [PMID: 7250179]
30 Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA "Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity." N Engl J Med 297 (1977): 630-4. [PMID: 302412]